albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
=== Hydraulic functions === The restriction of blood flow can also be used in specialized tissues to cause engorgement, resulting in an erection of that tissue; examples are the erectile tissue in the penis and clitoris. Another example of a hydraulic function is the jumping spider, in which blood forced into the legs under pressure causes them to straighten for a powerful jump, without the need for bulky muscular legs.
Around half of e-cigarette company websites have a minimum age notice that prohibited underage individuals from entering. Celebrity endorsements are used to encourage e-cigarette use. Opponents of the tobacco industry state that the Blu advertisement, in a context of longstanding prohibition of tobacco advertising on television, seems to have resorted to advertising tactics that got former generations of people in the US addicted to traditional cigarettes.
In petroleum engineering, in situ techniques involve the application of heat or solvents to extract heavy crude oil or bitumen from reservoirs located beneath the Earth's surface. Several in situ methods exist, but those that utilize heat, particularly steam, have proven to be the most effective for oil sands extraction. The most widely used in situ technique is steam-assisted gravity drainage (SAGD). This method employs two horizontal wells: the upper well injects steam to heat the bitumen, reducing its viscosity, while the lower well collects the mobilized oil for extraction. SAGD has gained prominence in the Canadian province of Alberta, due to its efficiency in recovering bitumen from deep reservoirs. Approximately 80% of Alberta's oil sands deposits are located at depths that render open-pit mining impractical, making in situ techniques such as SAGD the primary method of extraction.
=== Content protection === DisplayPort 1.0 includes optional DPCP (DisplayPort Content Protection) from Philips, which uses 128-bit AES encryption. It also features full authentication and session key establishment. Each encryption session is independent, and it has an independent revocation system. This portion of the standard is licensed separately. It also adds the ability to verify the proximity of the receiver and transmitter, a technique intended to ensure users are not bypassing the content protection system to send data out to distant, unauthorized users. DisplayPort 1.1 added optional implementation of industry-standard 56-bit HDCP (High-bandwidth Digital Content Protection) revision 1.3, which requires separate licensing from the Digital Content Protection LLC. DisplayPort 1.3 added support for HDCP 2.2, which is also used by HDMI 2.0.
Sources: en.wikipedia.org
In November 1944, the division and several attached units were redesignated as Panzerkorps Großdeutschland. By March 1945, the Panzer Grenadier Division Großdeutschland had been reduced to around 4,000 men after the Battle of Memel. It had only one Sturmgeschütz III self-propelled gun, one Panzer IV, five Panthers, and six Tiger Is by 15 March 1945. By 25 April, the division was engaged in heavy fighting in the battles around Pillau. Eight hundred men of the division were evacuated on ferries via the Baltic Sea and surrendered to British forces in Schleswig-Holstein on 9 May. The rest were either killed or captured during the fighting in Pillau or surrendered to Soviet forces on 9 May on the Vistula spit.
=== Spectrum of susceptibility === Doxycycline has been used successfully to treat sexually transmitted, respiratory, and eye infections. Representative pathogenic genera include Chlamydia, Streptococcus, Ureaplasma, Mycoplasma, and others. The minimum inhibitory concentration for a few medically significant microorganisms are:
=== Enantiomers === Tianeptine is a racemic mixture of (R)- and (S)- enantiomers. The (S)- enantiomer is known as estianeptine. (R)-Tianeptine is a weak μ-opioid receptor agonist, while estianeptine is a peroxisome proliferator-activated receptor (PPAR) agonist.
A classic example is two seeds of genetically identical corn, one placed in a temperate climate and one in an arid climate (lacking sufficient waterfall or rain). While the average height the two corn stalks could grow to is genetically determined, the one in the arid climate only grows to half the height of the one in the temperate climate due to lack of water and nutrients in its environment.
=== 2000s === 2001: spins off its Microelectronics Division (30% of its revenue), that becomes Mykrolis, which will merge with Entegris in 2005 2002: opens Biopharmaceutical Technology Center in Billerica, Massachusetts 2005: acquires MicroSafe, a European contract testing laboratory 2005: acquires NovAseptic, supplier of aseptically designed components for biotech and pharmaceutical production 2005: forms alliance with Gen-Probe to develop, manufacture and commercialize products for rapid microbiological and virus monitoring 2006: acquires Newport Bio Systems, a maker of process containers and systems used in biopharmaceutical production 2006: acquires Serologicals Corporation (including the companies Chemicon, Upstate, Linco, and Celliance), expanding its drug discovery and development footprint 2006: opens a new Research and Development Center in Bedford, Massachusetts 2007: launches its new brand 2008: expands drug discovery and development facility in St. Charles, Missouri 2008: opens membrane casting manufacturing facility in Carrigtwohill, County Cork, Ireland 2009: acquires Guava Technologies, a provider of bench top cell analysis systems 2009: opens Biomanufacturing Sciences and Training Center in Singapore 2009: acquires BioAnaLab, a European-based firm specializing in the analysis of biologic drugs and vaccines 2010: Merck KGaA acquires Millipore, which will be part of the EMD Group 2015: Merck completes $17 billion acquisition of Sigma-Aldrich, combining EMD Millipore and Sigma-Aldrich to create life science company MilliporeSigma
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.